<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02108821</url>
  </required_header>
  <id_info>
    <org_study_id>PRO13030081</org_study_id>
    <nct_id>NCT02108821</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation in Pediatric Patients</brief_title>
  <acronym>FMT</acronym>
  <official_title>A Study of Fecal Microbiota Transplantation in Pediatric Patients With Relapsed Inflammatory Bowel Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Mercy Hospital Kansas City</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A disturbance in the diversity of gut bacterial composition could be linked to several immune&#xD;
      mediated diseases including inflammatory bowel diseases (IBD). IBD can be classified into&#xD;
      Crohn's Disease (CD) and Ulcerative Colitis (UC). Both these diseases occur from abnormal&#xD;
      immune reaction to resident gut bacteria.The process of fecal microbiota transplantation&#xD;
      (FMT) where fecal bacteria from a healthy individual is transferred into a recipient, has&#xD;
      recently received attention as an alternative therapy for individuals affected with these&#xD;
      life-altering diseases. In this study, the investigators will perform fecal transplantation&#xD;
      on the subjects meeting inclusion criteria, to determine the efficacy and safety of this&#xD;
      therapy in subjects with IBD (CD and UC) who are not responding to first line therapy, and&#xD;
      are in a flare.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      50 subjects (25 subjects with Crohn's Disease and 25 subjects with Ulcerative Colitis) who&#xD;
      are 2 to 22 years of age will be enrolled in the trial over 3 years. The fecal donors,&#xD;
      preferably a parent or sibling, will be extensively screened for infectious diseases prior to&#xD;
      providing stool for the transplant. Patients who are failing primary therapy, are in a flare,&#xD;
      and require restaging of their IBD by an endoscopy and colonoscopy will be approached for the&#xD;
      study. Standard of care endoscopy and colonoscopy will be performed on each subject and 2&#xD;
      additional biopsies will be taken for analysis. Microbiota analysis will also be performed on&#xD;
      both the donor and recipient stool sample prior to transplantation, and on the recipient&#xD;
      sample at 1 week, 1 month, and 6 months post transplantation. The primary objective will be&#xD;
      to study the safety of FMT in all enrolled subjects. The study will also correlate efficacy&#xD;
      and patient outcomes with the fecal microbiome prior to, and after FMT. The secondary&#xD;
      objectives are to examine the efficacy of FMT in the treatment of children with IBD using the&#xD;
      Pediatric Ulcerative Colitis Activity Index (PUCAI) and the Pediatric Crohn Disease Activity&#xD;
      Index (PCDAI) analysis. Correlate the patient outcomes with the fecal microbiome prior to,&#xD;
      and after FMT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">September 30, 2016</completion_date>
  <primary_completion_date type="Actual">September 30, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Occurrences of Adverse Events at 6 Months According to Adverse Event Term</measure>
    <time_frame>6 months</time_frame>
    <description>Adverse events recorded to determine safety of Fecal Microbiome Transplant in the treatment of children with IBD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Examine the Efficacy of Fecal Microbiome Transplant in the Treatment of Children With IBD Using the Pediatric Ulcerative Colitis Activity Index (PUCAI) and the Pediatric Crohn Disease Activity Index (PCDAI) Analysis.</measure>
    <time_frame>Baseline, Day 30, Day 180</time_frame>
    <description>Efficacy outcomes scored via Pediatric Ulcerative Colitis Activity Index (PUCAI) and the Pediatric Crohn Disease Activity Index (PCDAI) analysis.&#xD;
Scored at baseline, day 30, and at day 180 for responders.&#xD;
The PUCAI score range is 0-85, where the higher the number the more severe the disease (A score of 65 and up is considered severe, a score of 35-64 is considered moderate, and a score of 10-34 is considered mild). The PUCAI is the scoring system used for patients with ulcerative colitis/indeterminate colitis.&#xD;
The PCDAI score range is 0-100, where the higher the number the more severe the disease (A score of greater than 30 is considered moderate to severe, a score of 11-30 is considered mild, and a score of 10 or less is considered inactive disease). The PCDAI is the scoring system used for patients with crohn's disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Inflammatory Bowel Diseases (IBD)</condition>
  <condition>Crohn's Disease (CD)</condition>
  <condition>Ulcerative Colitis (UC)</condition>
  <arm_group>
    <arm_group_label>Fecal Microbiome Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiome Transplantation will be done at the time of EGD and colonoscopy. A parent or sibling or a healthy relative will be tested for several infections like hepatitis, H. Pylori, HIV, syphilis, ova and parasites, culture and C.diff. They will fill out a donor questionnaire used for blood donors prior to the sample collection. After eligibility criteria have been met, appropriate consent has been obtained, and the screening labs have been assessed, the fecal transplant procedure will take place in the procedure center at Children's Hospital of Pittsburgh. Fresh stool sample will be obtained from the donor. The fecal sample will be prepared for transplantation in a designated area in the procedure center. Frequency: once. Duration: Approximately 1 hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation (FMT)</intervention_name>
    <description>The process of fecal microbiota transplantation (FMT), where fecal bacteria from a healthy individual is transferred into a recipient as an alternative therapy for individuals affected with these life-altering diseases: Crohn's Disease (CD), and/or Ulcerative Colitis (UC).</description>
    <arm_group_label>Fecal Microbiome Transplantation</arm_group_label>
    <other_name>Fecal Transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        STUDY SUBJECT INCLUSION CRITERIA:&#xD;
&#xD;
        Current IBD patients who have:&#xD;
&#xD;
          -  UC patients with a flare due to failure of current therapy and have to undergo&#xD;
             esophagogastroduodenoscopy (EGD) and colonoscopy for restaging the disease and&#xD;
             escalation of therapy.&#xD;
&#xD;
          -  CD patients with ileo colonic or colonic disease who require an EGD and colonoscopy&#xD;
             for disease assessment due to a flare or poor control.&#xD;
&#xD;
          -  The ability to safely undergo colonoscopy (physical status classification used by the&#xD;
             American Society of Anesthesiologists).&#xD;
&#xD;
          -  PUCAI score less than sixty five.&#xD;
&#xD;
          -  PCDAI score less than forty.&#xD;
&#xD;
        STUDY SUBJECTS EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Patients with Crohn's disease: complications like an abscess, phlegmon, stricture,&#xD;
             small bowel obstruction, perforation, internal or external fistulization or infection&#xD;
             as causes for flare up before being deemed eligible for recruitment to the study. We&#xD;
             will check for these complications if a recent study has not been done.&#xD;
&#xD;
          -  Severe immunosuppression: Biologicals with concomitant steroids (&gt;30 mg/day).&#xD;
&#xD;
          -  Central Line.&#xD;
&#xD;
          -  Pressor or ventilatory support.&#xD;
&#xD;
          -  On antibiotics.&#xD;
&#xD;
          -  Patients with Crohn's disease found to have complications like an abscess, phlegmon,&#xD;
             stricture, small bowel obstruction, perforation, internal or external fistulization or&#xD;
             infection.&#xD;
&#xD;
          -  Not willing to consent or follow guidelines throughout research trial.&#xD;
&#xD;
          -  Screening labs in either donor or recipient reveal problems with performing fecal&#xD;
             microbiome transplantation because inclusion requirements are no longer met.&#xD;
&#xD;
          -  Physician discretion.&#xD;
&#xD;
          -  Participant request.&#xD;
&#xD;
        DONOR EXCLUSION CRITERIA:&#xD;
&#xD;
          -  A history of antibiotic treatment during the 3 months preceding donation.&#xD;
&#xD;
          -  A history of intrinsic gastrointestinal illnesses.&#xD;
&#xD;
          -  A history of autoimmune or atopic illness or modulating therapy.&#xD;
&#xD;
          -  A history of chronic pain syndromes, or neurologic or neurodevelopmental disorders.&#xD;
&#xD;
          -  Metabolic syndrome or malnutrition or obesity.&#xD;
&#xD;
          -  A history of exposure to infectious agents.&#xD;
&#xD;
          -  Diarrhea or other symptoms of an intestinal infection within two weeks prior to, or on&#xD;
             the day of, stool donation.&#xD;
&#xD;
          -  A history of malignant illnesses or ongoing oncologic therapy.&#xD;
&#xD;
          -  Weight less than 15 kgs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alka Goyal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 21, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2014</study_first_posted>
  <results_first_submitted>June 16, 2018</results_first_submitted>
  <results_first_submitted_qc>February 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 4, 2021</results_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammatory Bowel Diseases (IBD)</keyword>
  <keyword>Crohn's Disease (CD)</keyword>
  <keyword>Ulcerative Colitis (UC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02108821/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fecal Microbiome Transplantation-open Label</title>
          <description>Fecal Microbiome Transplantation will be done at the time of EGD and colonoscopy. A parent or sibling or a healthy relative will be tested for several infections like hepatitis, H. Pylori, HIV, syphilis, ova and parasites, culture and C.diff. They will fill out a donor questionnaire used for blood donors prior to the sample collection. After eligibility criteria have been met, appropriate consent has been obtained, and the screening labs have been assessed, the fecal transplant procedure will take place in the procedure center at Children's Hospital of Pittsburgh. Fresh stool sample will be obtained from the donor. The fecal sample will be prepared for transplantation in a designated area in the procedure center. Frequency: once. Duration: Approximately 1 hour&#xD;
Fecal Microbiota Transplantation (FMT): The process of fecal microbiota transplantation (FMT), where fecal bacteria from a healthy individual is transferred into a recipient as an alternative therapy for individuals affected</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fecal Microbiome Transplantation</title>
          <description>Use of Fecal Microbiome Transplantation for participants with IBD.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" lower_limit="8" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Outpatient Gastroenterology clinic Children's Hospital of Pittsburgh. Pittsburgh. Pennsylvania. USA</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Occurrences of Adverse Events at 6 Months According to Adverse Event Term</title>
        <description>Adverse events recorded to determine safety of Fecal Microbiome Transplant in the treatment of children with IBD.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>Overall Study Events</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Occurrences of Adverse Events at 6 Months According to Adverse Event Term</title>
          <description>Adverse events recorded to determine safety of Fecal Microbiome Transplant in the treatment of children with IBD.</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate Abdominal Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flatulence and Bloating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emesis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloody Stools</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Examine the Efficacy of Fecal Microbiome Transplant in the Treatment of Children With IBD Using the Pediatric Ulcerative Colitis Activity Index (PUCAI) and the Pediatric Crohn Disease Activity Index (PCDAI) Analysis.</title>
        <description>Efficacy outcomes scored via Pediatric Ulcerative Colitis Activity Index (PUCAI) and the Pediatric Crohn Disease Activity Index (PCDAI) analysis.&#xD;
Scored at baseline, day 30, and at day 180 for responders.&#xD;
The PUCAI score range is 0-85, where the higher the number the more severe the disease (A score of 65 and up is considered severe, a score of 35-64 is considered moderate, and a score of 10-34 is considered mild). The PUCAI is the scoring system used for patients with ulcerative colitis/indeterminate colitis.&#xD;
The PCDAI score range is 0-100, where the higher the number the more severe the disease (A score of greater than 30 is considered moderate to severe, a score of 11-30 is considered mild, and a score of 10 or less is considered inactive disease). The PCDAI is the scoring system used for patients with crohn's disease.</description>
        <time_frame>Baseline, Day 30, Day 180</time_frame>
        <population>Only participants that responded to treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Fecal Microbiome Transplantation Ulcerative Colitis/Indeterminate Colitis</title>
            <description>Use of Fecal Microbiome Transplantation for participants with Ulcerative Colitis/Indeterminate Colitis.</description>
          </group>
          <group group_id="O2">
            <title>Fecal Microbiome Transplantation With Crohn's Disease</title>
            <description>Use of Fecal Microbiome Transplantation for participants with Crohn's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Examine the Efficacy of Fecal Microbiome Transplant in the Treatment of Children With IBD Using the Pediatric Ulcerative Colitis Activity Index (PUCAI) and the Pediatric Crohn Disease Activity Index (PCDAI) Analysis.</title>
          <description>Efficacy outcomes scored via Pediatric Ulcerative Colitis Activity Index (PUCAI) and the Pediatric Crohn Disease Activity Index (PCDAI) analysis.&#xD;
Scored at baseline, day 30, and at day 180 for responders.&#xD;
The PUCAI score range is 0-85, where the higher the number the more severe the disease (A score of 65 and up is considered severe, a score of 35-64 is considered moderate, and a score of 10-34 is considered mild). The PUCAI is the scoring system used for patients with ulcerative colitis/indeterminate colitis.&#xD;
The PCDAI score range is 0-100, where the higher the number the more severe the disease (A score of greater than 30 is considered moderate to severe, a score of 11-30 is considered mild, and a score of 10 or less is considered inactive disease). The PCDAI is the scoring system used for patients with crohn's disease.</description>
          <population>Only participants that responded to treatment</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="38.04" upper_limit="41.96"/>
                    <measurement group_id="O2" value="11.6" lower_limit="9.64" upper_limit="13.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 in responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="9.64" upper_limit="13.56"/>
                    <measurement group_id="O2" value="1.6" lower_limit="0" upper_limit="3.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180 in responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" lower_limit="19.64" upper_limit="23.56"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fecal Microbiota Transplantation</title>
          <description>Use of Fecal Microbiota Transplantation for participants with IBD.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Flatulence and bloating</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Emesis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Bloody stools</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>small number of subjects, open label trial, fecal calprotectin not collected in every subject so response measurement was subjective</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alka Goyal MD</name_or_title>
      <organization>Children's Mercy Hospital, Kansas City</organization>
      <phone>816-302-3069</phone>
      <email>agoyal4@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

